GLP 1: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%)

Selected angle: source

One-sentence thesis

The cited direct receipts support a bounded working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo.

Interpretation note: This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.

Why this is surprising

The surprise is bounded to the cited receipt bundle; separate direct sources report measurable effects in adults with overweight or obesity without diabetes; adults with overweight or obesity with at least one weight-related comorbidity, without diabetes; patients with overweight or obesity without diabetes mellitus. Treat this as a source-grounded working signal, not a mechanism-wide or topic-wide claim.

Evidence Landscape

Bounded research question: Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?

Evidence receipts

• fact_id=161900 (A_core) — Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%) source=Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults Wit
• fact_id=158054 (A_core) — Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo source=Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or O
• fact_id=145390 (A_core) — Gastrointestinal adverse events were reported more often with semaglutide than with placebo (82.2% versus 53.9%). doi=10.1038/s41591-022-02026-4
• fact_id=100298 (A_core) — serious adverse events were not statistically significant: OR of 1.06 (p = 0.82) doi=10.1111/obr.13792
• fact_id=149514 (A_core) — semaglutide (1.8%) versus placebo (2.2%) doi=10.1038/s41591-024-03015-5

Context receipts

Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim.

• fact_id=161899 (A_core) — 55.8% vs 13.2%, respectively; P < .001 source=Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults Wit
• fact_id=75386 (A_core) — a greater proportion treated with semaglutide were normoglycemic (69.5% vs. 35.8%; P < 0.0001) doi=10.2337/dc24-0491

What this changes

Treat this as a focused working signal, not a broad topic claim. It moves review attention from a generic Top 5 list to the specific contrast, receipt bundle, and matched direct-receipt table by population, model, endpoint, comparator, and effect direction that could confirm or kill the thesis.

Limitations

• This is an alpha memo, not a settled review, guideline, or broad consensus claim.
• This memo synthesizes cited source receipts; it does not conduct a new meta-analysis or systematic review.
• Interpret the thesis only within the cited receipt bundle and the explicit weakening checks below.
• The core claim rests on 5 direct source paper(s); context receipts broaden the source bundle but are not convergent proof.
• Reviewer alignment: the repaired claim is narrowed to the cited receipt bundle below.
• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

What would weaken this

• Independent receipts fail to reproduce the claimed contrast.
• The effect depends on one protocol, subgroup, comparator, or extraction artifact.

Strongest counter-evidence

• fact_id=100298 (A_core) — serious adverse events were not statistically significant: OR of 1.06 (p = 0.82) Source: Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—
• fact_id=139252 (A_core) — The incidence of thyroid cancer in semaglutide-treated patients was less than 1%, suggesting no significant risk. Source: Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Sys